🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Rare Cancers

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a1 site📍 Sioux Falls Sanford Health Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients NCT07147465n/a3 sites📍 Lyon📍 Paris📍 Paris Assistance Publique - Hôpitaux de Paris Rare Embryonal Tumors of the Central Nervous System: International Registry NCT05711992n/a11 sites📍 Yerevan📍 Ottawa📍 Budapest Immune Oncology Research Institute DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers NCT05770037Phase 2, Phase 327 sites📍 Belfast📍 Birmingham📍 Birmingham Cancer Research UK · Tests: Alectinib DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition NCT05770102Phase 2, Phase 327 sites📍 Belfast📍 Birmingham📍 Birmingham Cancer Research UK · Tests: Atezolizumab A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies NCT04923178n/a1 site📍 Bethesda National Cancer Institute (NCI) A Study of Pembrolizumab in People With Ultra-Rare Sarcomas NCT07089992Phase 27 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Pembrolizumab The Sarcoma Biology and Outcome Project NCT04758325n/a1 site📍 Heidelberg Prof. Dr. Richard F Schlenk Influencing Next-Generation Oncologic Outcomes Through Rapid Integration of Functional Precision Medicine (NOORI): A Feasibility Study of SmartMatch in Rare Gynecologic Cancers NCT07731880n/a1 site📍 Seattle Fred Hutchinson Cancer Center Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma NCT07314216Phase 21 site📍 Changsha Hunan Cancer Hospital · Tests: Firmonertinib, Definitive Thoracic Radiotherapy European Rare Blood Disorders Platform (ENROL) NCT06250595n/a1 site📍 Barcelona Hospital Universitari Vall d'Hebron Research Institute · Tests: Collection of clinical and laboratory data from EHR. Treatment Guided by Comprehensive Genome and Transcriptome Analysis Versus Standard of Care in Advanced Rare Cancers NCT06855134n/a16 sites📍 Augsburg📍 Berlin📍 Cologne German Cancer Research Center A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors NCT07070232Phase 1, Phase 277 sites📍 Phoenix📍 San Francisco📍 Hartford BioNTech SE · Tests: BNT326, Pumitamig, Itraconazole, Paroxetine GROWing Up With Rare GENEtic Syndromes NCT04463316n/a1 site📍 Rotterdam dr. Laura C. G. de Graaff-Herder · Tests: Retrospective file studies Protocol N. 2014 - Observational Study on the Quality of Life of Outpatients NCT06193850n/a1 site📍 Milan IRCCS San Raffaele · Tests: Observation during time Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies NCT07309770Phase 21 site📍 Shanghai Sheng Zhang · Tests: SHR-A1811, Trastuzumab Rezetecan Registry Study on Rare Cancers in Korea NCT06746766n/a1 site📍 Seoul Yonsei University DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. NCT07440290Phase 2, Phase 327 sites📍 Belfast📍 Birmingham📍 Birmingham Cancer Research UK · Tests: Dabrafenib, Trametinib Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE) NCT04498767NA13 sites📍 Anderlecht📍 Ghent📍 Wilrijk European Organisation for Research and Treatment of Cancer … · Tests: Stereotactic body radiotherapy, Palliative RT Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group NCT03967834NA20 sites📍 Besançon📍 Bordeaux📍 Clermont-Ferrand Institut Claudius Regaud · Tests: Patient with Soft Tissue Sarcoma Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations NCT05701787n/a2 sites📍 Shanghai📍 Shanghai Shanghai Chest Hospital Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations NCT07185997Phase 3139 sites📍 Fullerton📍 Los Angeles📍 Orange ArriVent BioPharma, Inc. · Tests: Firmonertinib, EGFR-TKI inhibitor based on investigator's choice Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE) NCT06041503Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Pembrolizumab, Enfortumab vedotin Dabrafenib and/or Trametinib Rollover Study NCT03340506Phase 438 sites📍 Scottsdale📍 Bethesda📍 Columbus Novartis Pharmaceuticals · Tests: dabrafenib, trametinib Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors NCT01356290Phase 222 sites📍 Chicago📍 Boston📍 Grand Rapids Medical University of Vienna · Tests: Bevacizumab, Thalidomide, Celecoxib, Fenofibric acid, Etoposide FARD (RaDiCo Cohort) (RaDiCo-FARD) NCT05954416n/a15 sites📍 Bobigny📍 Bordeaux📍 Bordeaux Institut National de la Santé Et de la Recherche Médicale, … Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C... NCT06161532Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Sacituzumab govitecan, Atezolizumab A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers. NCT04166006Phase 21 site📍 Meldola Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IR… · Tests: Autologous DC vaccine, Interleukin-2 Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia NCT07247279n/a7 sites📍 Kazan'📍 Moscow📍 Novosibirsk AstraZeneca Diagnostic Value of Exome/ Genome Sequencing, Conventional Methods in Rare Diseases and Familial Tumor Syndromes NCT04731857n/a1 site📍 Tübingen University Hospital Tuebingen · Tests: Retrospective data analysis
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy